Ophthalmology. 2006 Nov;113(11):1974-86. doi: 10.1016/j.ophtha.2006.08.015.
To evaluate the efficacy and safety of low-intensity laser treatment in the prevention of visual acuity (VA) loss among participants with bilateral large drusen.
Multicenter randomized clinical trial. One eye of each participant was assigned to treatment, and the contralateral eye was assigned to observation.
A total of 1052 participants who had > or =10 large (>125 microm) drusen and VA> or =20/40 in each eye enrolled through 22 clinical centers.
The initial laser treatment protocol specified 60 barely visible burns applied in a grid pattern within an annulus between 1500 and 2500 mum from the foveal center. At 12 months, eyes assigned to treatment that had sufficient drusen remaining were retreated with 30 burns by targeting drusen within an annulus between 1000 and 2000 mum from the foveal center.
Proportion of eyes at 5 years with loss of > or =3 lines of VA from baseline. Secondary outcome measures included the development of choroidal neovascularization or geographic atrophy (GA), change in contrast threshold, change in critical print size, and incidence of ocular adverse events.
At 5 years, 188 (20.5%) treated eyes and 188 (20.5%) observed eyes had VA scores > or = 3 lines worse than at the initial visit (P = 1.00). Cumulative 5-year incidence rates for treated and observed eyes were 13.3% and 13.3% (P = 0.95) for choroidal neovascularization and 7.4% and 7.8% (P = 0.64) for GA, respectively. The contrast threshold doubled in 23.9% of treated eyes and in 20.5% of observed eyes (P = 0.40). The critical print size doubled in 29.6% of treated eyes and in 28.4% of observed eyes (P = 0.70). Seven treated eyes and 14 observed eyes had an adverse event of a > or =6-line loss in VA in the absence of late age-related macular degeneration or cataract.
As applied in the Complications of Age-Related Macular Degeneration Prevention Trial, low-intensity laser treatment did not demonstrate a clinically significant benefit for vision in eyes of people with bilateral large drusen.
评估低强度激光治疗在预防双侧大玻璃膜疣患者视力丧失方面的疗效和安全性。
多中心随机临床试验。每位参与者的一只眼睛被分配接受治疗,对侧眼睛被分配进行观察。
通过22个临床中心招募了总共1052名参与者,他们每只眼睛有≥10个大(>125微米)玻璃膜疣且视力≥20/40。
初始激光治疗方案规定在距黄斑中心1500至2500微米的环形区域内以网格模式施加60个几乎不可见的烧灼。在12个月时,分配接受治疗且仍有足够玻璃膜疣残留的眼睛,通过针对距黄斑中心1000至2000微米的环形区域内的玻璃膜疣再次进行30次烧灼。
5年后视力较基线下降≥3行的眼睛比例。次要观察指标包括脉络膜新生血管或地图样萎缩(GA)的发生情况、对比阈值的变化、临界印刷字体大小的变化以及眼部不良事件的发生率。
5年后,188只(20.5%)接受治疗的眼睛和188只(20.5%)观察的眼睛视力评分比初次就诊时下降≥3行(P = 1.00)。接受治疗和观察的眼睛脉络膜新生血管的5年累积发生率分别为13.3%和13.3%(P = 0.95),GA的发生率分别为7.4%和7.8%(P = 0.64)。治疗组23.9%的眼睛和观察组20.5%的眼睛对比阈值翻倍(P = 0.40)。治疗组29.6%的眼睛和观察组28.4%的眼睛临界印刷字体大小翻倍(P = 0.70)。在没有晚期年龄相关性黄斑变性或白内障的情况下,7只接受治疗的眼睛和14只观察的眼睛出现了视力下降≥6行的不良事件。
在年龄相关性黄斑变性预防试验并发症研究中应用的低强度激光治疗,对于双侧大玻璃膜疣患者的眼睛视力并未显示出临床上的显著益处。